Contents

Current Cancer Drug Targets, Volume 10 - Number 7

Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases

, 10(7): 649 - 659

M. Salerno, E. Cenni, C. Fotia, S. Avnet, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, M. Capulli, N. Rucci, A. Angelucci, A. Del Fattore, A. Teti, N. Zini, A. Giunti and N. Baldini


DOI: 10.2174/156800910793605767




Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel

, 10(7): 660 - 669

Z. Khan, N. Khan, A. K. Varma, R. P. Tiwari, S. Mouhamad, G. B.K.S. Prasad and P. S. Bisen


DOI: 10.2174/156800910793605866




The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum-Induced Peripheral Neurotoxicity

, 10(7): 670 - 682

V. A. Carozzi, P. Marmiroli and G. Cavaletti


DOI: 10.2174/156800910793605820




Is Src a Viable Target for Treating Solid Tumours?

, 10(7): 683 - 694

B. Elsberger, B. Stewart, O. Tatarov and J. Edwards


DOI: 10.2174/156800910793605802




Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept

, 10(7): 695 - 704

C. Falciani, B. Lelli, J. Brunetti, S. Pileri, A. Cappelli, A. Pini, C. Pagliuca, N. Ravenni, L. Bencini, S. Menichetti, R. Moretti, M. De Prizio, M. Scatizzi and L. Bracci


DOI: 10.2174/156800910793605875




Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non – Small Cell Lung Cancer Models

, 10(7): 705 - 715

Z. W. Gao, D. L. Zhang and C. B. Guo


DOI: 10.2174/156800910793605776




Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options

, 10(7): 716 - 727

R. K. Gandhirajan, S. J. Poll-Wolbeck, I. Gehrke and K.-A. Kreuzer


DOI: 10.2174/156800910793605794




New Insights of CTLA-4 into Its Biological Function in Breast Cancer

, 10(7): 728 - 736

H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu


DOI: 10.2174/156800910793605811




Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results

, 10(7): 737 - 757

N. Castagnino, L. Tortolina, A. Balbi, R. Pesenti, R. Montagna, A. Ballestrero, D. Soncini, E. Moran, A. Nencioni and S. Parodi


DOI: 10.2174/156800910793605848




DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy

, 10(7): 758 - 771

K. Chikamori, A. G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi and M. K. Ganapathi


DOI: 10.2174/156800910793605785




Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

, 10(7): 772 - 781

C. D'Alterio, C. Consales, M. Polimeno, R. Franco, L. Cindolo, L. Portella, M. Cioffi, R. Calemma, L. Marra, L. Claudio, S. Perdona, S. Pignata, G. Facchini, G. Carteni, N. Longo, L. Pucci, A. Ottaiano, S. Costantini, G. Castello and S. Scala


DOI: 10.2174/156800910793605839




Cancer Therapy By Targeting Hypoxia-Inducible Factor-1

, 10(7): 782 - 796

Y. Li and D. Ye


DOI: 10.2174/156800910793605857




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science